
|Videos|July 23, 2021
First Vyluma product tackles pediatric myopia
Advertisement
Dive deep into Vyluma’s investigational atropine therapy. Navneet Puri, PhD, the company’s founder, chairman, and CEO, explains details of the clinical trials.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Optometry Times - Clinical News & Expert Optometrist Insights
1
FDA expands TearCare indication to improve meibomian gland function
2
Catching keratoconus early in pediatric patients: Why timing matters
3
FDA accepts NDA for bimatoprost grenod in open-angle glaucoma and OHT
4
Not all myopia is the same: Noha Ekdawi, MD, FAAP, on individualized management
5
















